BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17333195)

  • 1. Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.
    Scott J; Dorr RT; Samulitis B; Landowski TH
    Cancer Chemother Pharmacol; 2007 May; 59(6):749-57. PubMed ID: 17333195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent.
    Evens AM; Prachand S; Shi B; Paniaqua M; Gordon LI; Gartenhaus RB
    Clin Cancer Res; 2004 Feb; 10(4):1481-91. PubMed ID: 14977852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells.
    Samulitis BK; Dorr RT; Chow HH
    Anticancer Res; 2011 Sep; 31(9):2781-5. PubMed ID: 21868520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlates of imexon sensitivity in human multiple myeloma cell lines.
    Samulitis BK; Landowski TH; Dorr RT
    Leuk Lymphoma; 2006 Jan; 47(1):97-109. PubMed ID: 16321833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma.
    Weber JS; Samlowski WE; Gonzalez R; Ribas A; Stephenson J; O'Day S; Sato T; Dorr R; Grenier K; Hersh E
    Cancer; 2010 Aug; 116(15):3683-91. PubMed ID: 20564083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of mitochondrial changes in myeloma cells by imexon.
    Dvorakova K; Waltmire CN; Payne CM; Tome ME; Briehl MM; Dorr RT
    Blood; 2001 Jun; 97(11):3544-51. PubMed ID: 11369649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
    Kaufmann SH; Peereboom D; Buckwalter CA; Svingen PA; Grochow LB; Donehower RC; Rowinsky EK
    J Natl Cancer Inst; 1996 Jun; 88(11):734-41. PubMed ID: 8637027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro.
    Hersh EM; Gschwind CR; Taylor CW; Dorr RT; Taetle R; Salmon SE
    J Natl Cancer Inst; 1992 Aug; 84(16):1238-44. PubMed ID: 1640482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells.
    Dvorakova K; Payne CM; Tome ME; Briehl MM; Vasquez MA; Waltmire CN; Coon A; Dorr RT
    Mol Cancer Ther; 2002 Jan; 1(3):185-95. PubMed ID: 12467213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma.
    Moehler TM; Feneberg R; Ho AD; Golenkov AK; Ludwig H; Kropff M; Khuageva NK; Hajda J; von Broen I; Goldschmidt H
    Anticancer Drugs; 2010 Aug; 21(7):708-15. PubMed ID: 20571355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon.
    Dvorakova K; Payne CM; Tome ME; Briehl MM; McClure T; Dorr RT
    Biochem Pharmacol; 2000 Sep; 60(6):749-58. PubMed ID: 10930529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase.
    Roman NO; Samulitis BK; Wisner L; Landowski TH; Dorr RT
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):183-92. PubMed ID: 20339847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
    Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
    von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
    Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
    Siegel MB; Liu SQ; Davare MA; Spurgeon SE; Loriaux MM; Druker BJ; Scott EC; Tyner JW
    Oncotarget; 2015 Aug; 6(22):18921-32. PubMed ID: 26254279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.
    Adjei AA; Budihardjo II; Rowinsky EK; Kottke TJ; Svingen PA; Buckwalter CA; Grochow LB; Donehower RC; Kaufmann SH
    Clin Cancer Res; 1997 May; 3(5):761-70. PubMed ID: 9815747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines.
    Dorr RT; Raymond MA; Landowski TH; Roman NO; Fukushima S
    Int J Gastrointest Cancer; 2005; 36(1):15-28. PubMed ID: 16227632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines.
    Photiou A; Shah P; Leong LK; Moss J; Retsas S
    Eur J Cancer; 1997 Mar; 33(3):463-70. PubMed ID: 9155533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423.
    Dorr RT; Wisner L; Samulitis BK; Landowski TH; Remers WA
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1039-49. PubMed ID: 22186884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical pharmacokinetics and antitumor activity of imexon.
    Dorr RT; Liddil JD; Klein MK; Hersh EM
    Invest New Drugs; 1995; 13(2):113-6. PubMed ID: 8617572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.